Filozof C, Schwartz S, Foley JE. Effect of vildagliptin as add-on therapy to a low-dose metformin. World J Diabetes 2010; 1(1): 19-26 [PMID: 21537424 DOI: 10.4239/wjd.v1.i1.19]
Corresponding Author of This Article
Claudia Filozof, MD, PhD, Diabetes Principal Medical Scientific Expert, Novartis Pharma AG, Fabrikstrasse 4-4.43.4, CH-4056 Basel, Switzerland. claudia.filozof@novartis.com
Article-Type of This Article
Brief Articles
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/